Mimrylo Approval: How Rusfertide Treats Polycythemia Vera
FDA approved Mimrylo, or rusfertide, in August 2026 to control excess red blood cell production in certain adults with polycythemia vera.
Timeline
- August 28, 2026: FDA approved Mimrylo for erythrocytosis in adults with polycythemia vera.
- 32-week VERIFY trial period: Mimrylo and placebo were compared alongside standard therapy in adults requiring frequent phlebotomy.
The U.S. Food and Drug Administration approved Mimrylo, the brand name for rusfertide, on August 28, 2026. Its approved use is treatment of erythrocytosis in adults with polycythemia vera whose disease has not been adequately controlled with existing therapy. [1][2]
Polycythemia vera is a chronic blood disorder in which the body produces too many red blood cells. The excess can raise hematocrit, thicken the blood and increase the risk of problems including clots, stroke and heart attack. Keeping hematocrit below 45 percent is an important treatment goal described by FDA. [1]
Rusfertide is the first approved treatment for polycythemia vera that mimics hepcidin, a hormone involved in regulating iron. By limiting iron available for production of new red blood cells, it targets a resource the bone marrow needs and helps reduce overproduction rather than directly removing existing blood. [1]
Many patients use therapeutic phlebotomy, which removes blood from a vein to reduce red-cell volume. Mimrylo does not make monitoring unnecessary. Its approval offers another approach for adults who still required frequent phlebotomies despite standard therapy, with dosing adjusted to keep hematocrit below the target threshold. [1][2]
The Phase 3 VERIFY trial enrolled 293 adults and randomly assigned Mimrylo or placebo for 32 weeks while standard treatment continued. FDA reports that 76.9 percent of Mimrylo recipients required no phlebotomy during the assessed period, compared with 32.9 percent receiving placebo. [1]
Treatment began at 19 milligrams injected under the skin once weekly and was titrated according to hematocrit control. Injection-site reactions and anemia were the most common adverse reactions reported by FDA. Individual dosing, monitoring and management of low blood counts belong under the current prescribing information and specialist care. [1]
The approval does not mean rusfertide cures polycythemia vera or eliminates every cardiovascular risk. It establishes evidence for controlling erythrocytosis in the labeled population. Patients may still need other disease-directed therapy, blood tests and risk management based on age, clotting history, symptoms and response. [1][2]